Theophylline-platinum (IV) prodrug-1

Theophylline-platinum (IV) prodrug-1 is a PARP-1 inhibitor. Theophylline-platinum (IV) prodrug-1 enhances DNA damage, ROS production, mitochondrial dysfunction, apoptosis and S-phase arrest, along with reducing invasion and metastasis in cells. Theophylline-platinum (IV) prodrug-1 exhibits superior antitumor activity in the xenograft SKOV3-BRCA1-KD tumor model. Theophylline-platinum (IV) prodrug-1 can be used for the study of ovarian cancer[1].

Product Specifications

UNSPSC

12352005

Target

Apoptosis; Bcl-2 Family; Cadherin; EGFR; ERK; NF-κB; PARP; Reactive Oxygen Species (ROS) ; TGF-β Receptor

Related Pathways

Apoptosis; Cell Cycle/DNA Damage; Cytoskeleton; Epigenetics; Immunology/Inflammation; JAK/STAT Signaling; MAPK/ERK Pathway; Metabolic Enzyme/Protease; NF-κB; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt; TGF-beta/Smad

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Smiles

[NH3][Pt+4]([NH3])([O-]C(CN1C=NC(N(C(N2C)=O)C)=C1C2=O)=O)([O-]C(CCCCCCCCCCCCCCC)=O)([Cl-])[Cl-]

Molecular Formula

C25H46Cl2N6O6Pt

Molecular Weight

792.66

References & Citations

[1]Liu XM, et al. Precision-Oriented Theophylline-Platinum (IV) Prodrugs: Eliciting Synthetic Lethality in BRCA1-Deficient Ovarian Cancer with Enhanced Efficacy and Reduced Toxicity In Vitro and In Vivo. J Med Chem. 2025 Jul 24;68 (14) :14995-15014.